Solace Therapeutics raises $7M equity round
Solace Therapeutics Inc. of Framingham, which develops non-surgical treatments for common bladder disorders, has raised $7 million in equity financing out of a $20 million offering, according to forms filed with the U.S. Securities and Exchange Commission.
The company, headed by CEO Kevin Connors, makes the Solace AttenueX Balloon, a small device about the size of a quarter that floats in the urinary bladder. According to the company, it acts as a shock absorber to reduce the temporary pressure changes in the bladder that cause urinary leakage. The device can be placed by a physician using a catheter.